Serina Therapeutics Inc
SER5.130USD
-0.160-3.02%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
50.95MCap. mercado
PérdidaP/E TTM
Más Datos de Serina Therapeutics Inc Compañía
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Información de la empresa
Símbolo de cotizaciónSER
Nombre de la empresaSerina Therapeutics Inc
Fecha de salida a bolsaNov 29, 2018
Director ejecutivoMr. Steven Ledger
Número de empleados12
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 29
Dirección601 Genome Way,
CiudadHUNTSVILLE
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal35806
Teléfono12563279630
Sitio Webhttps://serinatherapeutics.com/
Símbolo de cotizaciónSER
Fecha de salida a bolsaNov 29, 2018
Director ejecutivoMr. Steven Ledger
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Director
Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Director
Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Desglose de ingresos
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 28 de may
Actualizado: mié., 28 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Juvenescence Ltd
32.78%
Puffinus L.P.
9.08%
McMillan (Helen w)
8.45%
Fisk (Barbara M.)
5.38%
Loya (Miguel)
4.23%
Other
40.08%
Accionistas
Accionistas
Proporción
Juvenescence Ltd
32.78%
Puffinus L.P.
9.08%
McMillan (Helen w)
8.45%
Fisk (Barbara M.)
5.38%
Loya (Miguel)
4.23%
Other
40.08%
Tipos de accionistas
Accionistas
Proporción
Corporation
41.86%
Individual Investor
21.99%
Investment Advisor
1.13%
Investment Advisor/Hedge Fund
1.12%
Hedge Fund
1.10%
Research Firm
0.04%
Other
32.76%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
59
6.70M
67.24%
+259.47K
2025Q1
61
6.74M
67.68%
+273.42K
2024Q4
60
6.52M
69.43%
+1.01M
2024Q3
60
5.48M
62.28%
+460.95K
2024Q2
62
5.34M
60.76%
+463.56K
2024Q1
62
4.83M
57.65%
+2.79M
2023Q4
55
610.31K
56.56%
+2.00K
2023Q3
59
606.40K
56.20%
-1.31K
2023Q2
62
604.05K
55.98%
-7.36K
2023Q1
65
604.47K
56.02%
-8.31K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Juvenescence Ltd
3.27M
32.78%
--
--
Mar 01, 2025
Puffinus L.P.
904.88K
9.08%
--
--
Mar 01, 2025
McMillan (Helen w)
842.40K
8.45%
+133.79K
+18.88%
Mar 01, 2025
Fisk (Barbara M.)
536.28K
5.38%
+33.81K
+6.73%
Mar 01, 2025
Loya (Miguel)
422.10K
4.23%
--
--
Mar 01, 2025
Ledger (Steven A)
323.66K
3.25%
+95.73K
+42.00%
Mar 28, 2025
Broadwood Capital, Inc.
85.22K
0.85%
--
--
Mar 31, 2025
Waverly Advisors, LLC
67.49K
0.68%
--
--
Mar 31, 2025
Bailey (Gregory Hugh)
67.24K
0.67%
--
--
Mar 01, 2025
The Vanguard Group, Inc.
65.33K
0.66%
+3.26K
+5.25%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Fecha
Tipo
Relación
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
